Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
A Phase 2b, 12-Week Study of VX-509, an Oral Selective Janus Kinase 3 Inhibitor, in Combination with Background Methotrexate in Rheumatoid Arthritis Genovese, M. C., van Vollenhoven, R., Bloom, B. J., Jiang, J. G., Kinnman, N. WILEY-BLACKWELL. 2013: 3320
View details for Web of Science ID 000327692600044